Home
 
CINOBUFOTALIN



RESEARCH

Effect of Cinobufacini Injection on proliferation and invasiveness of human hepatoma HepG-2 cells co-cultured with human lymphatic endothelial cells

Source:
Fu Hai-yan, Gao Shan, Tian Li-li, Chen Xiu-ying, Cui Xiao-nan. Effect of Cinobufacini Injection on proliferation and invasiveness of human hepatoma HepG-2 cells co-cultured with human lymphatic endothelial cells. Zhong Guo Lin Chuang Yao Li Xue Za Zhi. 2013, 29(3): 199-201.

To study the effect of Cinobufacini Injection on proliferation, heterogeneous adhesion and invasiveness of human hepatoma HepG-2 cells co-cultured with human lymphatic endothelial cells (HLEC) a co-culture system of human hepatoma HepG-2 cells and HLEC was established by means of Transwell chamber. Cell proliferation was analysed by Trypan blue stain assay. MTT assay was used to observe the heterogeneous adhesion capacity of HepG-2 cells co-cultured with HLEC. Transwell invasion chamber was used to observe the invasiveness capacity of HepG-2 cells co-cultured with HLEC. Cinobufacini Injection significantly inhibits proliferation, heterogeneous adhesion and invasiveness of hepG-2 cells co-cultured with HLEC in dose dependent ways (all P0.05). Cinobufacini Injection can inhibit the capability of proliferation, invasiveness and heterogeneous adhesion of HepG-2 cells, which might contribute to the inhibiting mechanisms of Cinobufacini Injection on tumor metastasis.



The effect of cinobufacini injection on proliferation and tube-like structure formation of human lymphatic endothelial cells

Source:
Gao Shan, Chen Xiu-ying, Fu Hai-yan, Cui Xiao-nan. The effect of cinobufacini injection on proliferation and tube-like structure formation of human lymphatic endothelial cells. Zhong Guo Ai Zheng Za Zhi. 2013, 23(1): 36-41.

The cinobufacini injection is a traditional antitumor drug. However, its mechanism is still unclear. The purpose of this study was to observe the effect of cinobufacini injection on proliferation, migration and tube-like structure formation of human lymphatic endothelial cells (HLEC). Cell growth curve was used to observe the effect of cinobufacini injection on the proliferation of HLEC; Migration assay was used to observe the effect of cinobufacini injection on the migration of HLEC; Matrigel assay was used to observe the effect of cinobufacini injection on the tube-like structure formation of HLEC; Western blot was used to analyze the expression of VEGFR-3 and HGF in HLEC under the action of cinobufacini injection. Results: With the increase of cinobufacini injection concentration (0.105, 0.21 and 0.42 μg/mL), HLEC inhibition rate gradually increased; Migration rates were 0.87±0.07, 0.69±0.05, and 0.37A0.02; and 1A0.03 in control group. HLEC into the tube rates were 0.90±0.06, 0.83±0.02, and 0.63±0.05; and 1±0.02 in control group. VEGFR-3/β-actin optical density ratios were 0.440±0.017, 0.618±0.100, and 0.803±0.091; and 1.030±0.017 in the control group. HGF/β-actin ratios of the optical density were 0.293±0.021, 0.540±0.027, and 0.760±0.087; and 0.940±0.020 in control group (P<0.05). Which showed that cinobufacini injection significantly inhibited HLEC proliferation (P<0.05), migration (P<0.05) and tube- like structure formation in dose dependent ways (P<0.05). Cinobufacini injection significantly decreased the expression of VEGFR-3 and HGF in HLEC in dose dependent ways (P<0.05). Cinobufacini injection significantly inhibits HLEC proliferation, migration and tube-like structure formation, and the down-regulation of VEGFR-3 and HGF may contribute to the inhibition of cinobufacini injection on HLEC.



Meta-Analysis of Cinobufacini Injection plus Chemotherapy in the Treatment of Non-small-cell Lung Cancer

Source:
Tu Chao, Yin Jun, He Jieyu. Meta-Analysis of Cinobufacini Injection plus Chemotherapy in the Treatment of Non-small-cell Lung Cancer. Zhong Liu Yao Xue. 2012, 2(1): 67-72.

To evaluate the efficacy and safety of cinobufacini injection combined with chemotherapy as the treatment for advanced non-small-cell lung cancer(NSCLC) based on existing clinical information, a search of databases, such as Medline (1966-2011), Cochrane Library (2011, Issue 11), CNKI (1978-2011), VIP (1989-2011), Wanfang Data (1988-2011), CBMdisc (1978-2011) was done. RevMan 5.0.2 software was used to undertake meta-analysis which included randomized controlled trials (RCT). A total of seven RCTs of 498 patients were included. Meta-analysis results show that the experimental group and control group have significant differences in the response rate[RR=1.29, 95%CI (1.07, 1.56)], Karnofsky score [RR=1.86, 95%CI(1.14, 3.05)], weight change [RR=1.56, 95%CI (1.20, 2.03)], gastrointestinal side effects[RR=0.72, 95%CI(0.53, 0.99)], neutropenia [RR=0.70, 95%CI(0.54, 0.91)], thrombocytopenia [RR=0.53, 95%CI(0.38, 0.75)], abnormal renal function [RR=0.37, 95%CI(0.17, 0.79)], and have no significant differences in abnormal liver function [RR=0.59, 95%CI(0.26, 1.34)] and neurotoxicity [RR=0.74, 95%CI(0.32, 1.75)]. Cinobufacini combined with chemotherapy is suitable for advanced NSCLC by improving the response rate, increasing Karnofsky score, gaining weight and reducing major side effects.



Clinical observation of patients with primary liver cancer treated by Cinobufagin Injection combined with transcatheter arterial chemoembolization

Source:
Ke Jun, Lu Kui, Li Yang. Clinical observation of patients with primary liver cancer treated by Cinobufagin Injection combined with transcatheter arterial chemoembolization. Zhong Guo Shi Yong Yi Yao. 2011, 6(34): 1-2.

To observe the clinical effect of Cinobufagin Injection combined with transcatheter arterial chemoembolization (TACE) on treating primary liver cancer; 78 patients with moderate and advanced primary liver cancer were randomly divided. The treatment group (n=38) was treated by Cinobufagin Injection combined with TACE, and control group (n=40), was treated by TACE only. The life quality of patients in treatment group was obviously higher than that in control group, and over 12 months the survival rate of the treatment group was significantly higher than that of control group, while the difference of the effective rate between the two groups had no statistically significance. The laboratory tests after three cycles in treatment group were better than that of control group, and the difference between the two groups was statistically significant. Cinobufagin Injection combined with TACE can decrease the damage on liver by TACE, prolong survival time, and improve body immunity.



Proliferation Inhibition and Cell Cycle Arrest of Human Hepatoma HepG-2 Cell Induced by Cinobufacini Injection

Source:
SUN Yu, LU Xin-xin, LIANG Xin-miao, CUI Xiao-nan. Proliferation Inhibition and Cell Cycle Arrest of Human Hepatoma HepG-2 Cell Induced by Cinobufacini Injection. Zhong Guo Yi Yao Zhi Nan. 2011, 9(28): 206-208.

The effects of cinobufacin injection on the proliferation and cell cycle of human hepatoma HepG-2 cells were studied. Proliferation was analysed by MTT assay; flow cytometry (FCM) was employed to detect tumor cell cycle distribution; expression of cyclinA, CDK2 mRNA levels in HepG-2 cells was analysed by PT-PCR; quantitative colorimetric assay was used to analyse cyclinA/CDK2 activity in HepG-2 cells. Cinobufacini injection significantly inhibited HepG-2 cells proliferation in a doses-and time-dependent manner; FCM analysis expressed cinobufacin injection induced cell cycle arrest at S phase; PT-PCR assay showed cinobufacin injection down-regulated CDK2, CyclinA expression at mRNA levels; quantitative colorimetric assay displayed cinobufacin injection deceased cyclinA/CDK2 activity in HepG-2 cells. Human hepotocarcinoma HepG-2 cell growth can be inhibited and cell cycle can be induced to arrest at S phase through injection. The mechanism might be partly related to the down-regulation of CDK2, CyclinA expression and inhibition of cyclinA/CDK2 activity.

 
CopyRight 2012 - ICOP